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Gy) followed by 3 weekly applications of intraluminal high 
dose rate brachytherapy (HDRBT)starting 6 weeks after EBRT. 
The starting dose level was 3x5 Gy with escalation of 1 Gy 
per fraction if acute toxicity was acceptable. Toxicity was 
acceptable if <2/6 patients or <3/9 patients exhibited dose 
limiting toxicity (DLT), defined as grade 3 proctitis (CTCAE v 
3.0), within 6 weeks after HDRBT. Secondary endpoints were 
severe treatment-related late toxicity, clinical tumor 
response and progression free survival (PFS). Clinical tumor 
response was evaluated based on all available endoscopy 
pictures and defined as complete clinical response (CR), 
partial response (PR), stable disease (SD) or progression (PD). 
 
Results: Thirty-eight patients with a mean age of 81 years, 
entered the study of whom 36 received HDRBT. Two patients 
died directly after HDRBT and 3 patients refused follow-up 
endoscopies, leaving 31 patients for response evaluation. At 
time of current analyses 13 patients were still alive, with a 
median FU of 30 months. Primary endpoint was reached at 
the 8 Gy dose-level with 3/9 patients showing a DLT. 
Response was observed in 25 patients (80.6%); of the 18 
patients achieving a CR, 6 developed progressive disease 
later on. Of the 7 patients with PR, 4 showed progression, 
whereas this occurred in 5/6 patients with SD. Median time 
to progression was 6.3 months. PFS at 1,2 and 3 years was 
65.6%, 46.4% and 22.1% respectively. Late treatment related 
grade 3/4 toxicity occurred in 13 patients, of those 9 patients 
also showed progressive disease. Outcomes related to 
doselevel are displayed in table 1. 
 
 
Conclusion: A combination of EBRT and HDRBT is feasible in 
inoperable elderly patients with acceptable acute toxicity 
and a promising overall response rate of 80.6%. However, 
given the observed toxicity, a randomized trial comparing 
EBRT with or without HDRBT boost is necessary. In this trial 
the clinical relevance of the added tumor control in light of 
additional toxicity from HDRBT will be evaluated in this 
fragile population. 
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Purpose or Objective: Radiation therapy is an established 
neoadjuvant modality for patients with advanced rectal 
cancer. As the quality of surgery improved with Total 
Mesorectal Excision surgery (TME), radiation is now being 
challenged, as the number of patients needed to treat 
remains high when facing long-term normal tissue toxicity in 
the pelvis. High dose rate endorectal brachytherapy is a 
highly targeted form of radiation based on quality imaging 
with magnetic resonant imaging and was introduced in our 
institution along with TME. Unlike external beam radiation 
therapy, the clinical target volume is aiming mostly at the 
tumor bed. We are reporting the patterns of relapse of our 
patients after 15 years experience. 
 
Material and Methods: Patients with operable rectal cancer 
based on pelvic MRI staging, are considered at risk for local 
recurrence were included; for physical reasons, those with 
obstructive tumors and positive extramesorectal nodes were 
excluded. Patients received treatment with 26 Gy in 4 
fractions using a remote afterloader with an endoluminal 
cylindrical multichannel applicator and an Iridium 192 
source. The CTV is defined as the gross tumor volume 
observed on the diagnostic MRI with no attempt to cover the 
perirectal nodes. 667 patients treated from 1999-2015, most 
of which were T3 tumors (84%), low T2 (13%) and early T4 
(3%); 36 % of the patients had positive nodes on pre-operative 
imaging. The local failure in our patient population is 4.7 % 
with a median follow up time of 65 months for 608 patients 
(range 6-165 months). Twenty-eight patients had pelvic 
recurrence, of which 25 were documented with MRI and 3 
were found with CT scan. The Imaging was reviewed by two 
radiologists. 
 
Results: The location of recurrence were identified as: iliac 
or lateral nodes in 11 patients, anastomotic in 10 patients, 
inguinal nodes in 3 patients, anterior compartment in 4 
patients and pre-sacral space in one patient (one patient had 
more than 2 sites). In the patients with nodal pelvic relapses, 
the relapse was isolated for 3 patients and in the other 8 
patients there were associated systemic relapses, and these 
patients were asymptomatic and did not require pelvic 
radiation while the former 3 patients underwent successful 
salvage radiation with IMRT (1) /SBRT for 2 patients. Another 
9 patients with isolated pelvic relapses received pre-
operative pelvic radiation with salvage surgery. 
 
Conclusion: In patients with rectal cancer treated with pre-
operative HDRBT, pelvic nodal relapse was the most common 
site of recurrence and was often associated with 
asymptomatic systemic relapse. Those patients with isolated 
nodal relapse are salvageable with either IMRT of SBRT. For 
patients with localized recurrence, pre-operative pelvic 
radiation was possible with salvage surgery. Pre sacral 
recurrence is a rare event, with a single patient observed. 
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Purpose or Objective: Locally advanced unresectable biliary 
carcinoma often present as extrahepatic malignant biliary 
obstruction with jaundice. The aim of treatment is to relieve 
jaundice and pruritus either by endoscopic biliary drainage 
(EBD) or percutaneous transhepatic biliary drainage (PTBD) 
followed by stenting. Stent is frequently blocked due to 
either tumour ingrowth or overgrowth. Intraluminal 
brachytherapy (ILBT) allows high dose to of radiation to local 
tumor area and delays the stent block. The purpose of this 
study is to assess the safety and efficacy of ILBT and impact 
of external beam radiotherapy(EBRT) on stent patency and 
survival. 
 
Material and Methods: From 1998-2008, 172 unresectable, 
locally advanced biliary cancers (pancreas-12, gallbladder-
140, cholangiocarcinoma-20), presenting with malignant 
extrahepatic biliary obstruction were prospectively treated 
with PTBD and stenting followed by ILBT with or without 
EBRT. The 110/172(64%) patients received ILBT alone (ILBT 
group) while 62/172(36%) received ILBT followed by 
EBRT(EBRT group). Endoscopic retrograde cholangio 
pancreaticography (ERCP) and/or percutaneous 
cholangiogram (PC) was done in all. Biliary drainage was done 
by standard ultrasound and fluoroscopy guided percutaneous 
transhepatic puncture. The stricture was dilated by balloon 
catheter over the guide wire. The biliary tract was dilated 
repeatedly and upsized till 12 French Malecot catheter. High 
